TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Windtree Therapeutics ( (WINT) ) has provided an update.
On November 25, 2025, Windtree Therapeutics issued $857,142.86 in senior convertible promissory notes due 2026 to fund the acquisition of CommLoan Inc. and for corporate purposes. The notes, which mature in 2026, include provisions for conversion into common stock, prepayment conditions, and adjustments in case of equity financing, impacting the company’s financial strategy and stakeholder interests.
Spark’s Take on WINT Stock
According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.
Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Recent corporate events provide a minor positive outlook, but overall, the stock presents considerable risks with limited upside potential without a substantial change in financial performance or market conditions.
To see Spark’s full report on WINT stock, click here.
More about Windtree Therapeutics
Windtree Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for critical care and pulmonary diseases.
Average Trading Volume: 336,934
Technical Sentiment Signal: Sell
Current Market Cap: $1.64M
For an in-depth examination of WINT stock, go to TipRanks’ Overview page.